Dengue - opportunities for diagnostics companies
This article was originally published in Clinica
The proliferation of dengue fever across the world's tropical latitudes and beyond the borders of endemic countries, has put the disease high on the global diagnostics agenda. Considerations that emerge from an assessment of the technologies available to diagnose the disease and the typical market dynamics that dictate their use, have wider implications for other population-wide screening technologies. Latin America is host to the current epidemic, writes Bernard Murphy.
You may also be interested in...
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.